J Clin Oncol: Primain's effect on radiation-related neuropathic pain in patients with head and neck cancer

In patients with radiotherapy for head and neck cancer, neuropathic pain is an inevitable treatment-related adverse eventThe purpose of this study was to test the efficacy and safety of Pribarin's placebo-related neuropathic painthe randomized, double-blind, placebo-controlled trial was conducted in four centers in ChinaEligible patients scored an average pain intensity of 4 or more on the 11-point numerical scale and were randomly assigned to be given a flexible dose of Pugabarin or a placebo for 16 weeksThe main therapeutic effect was pain relief measured on a numerical scaleA total of 128 patients were treated at randomAt week 16, the pain intensity of Pribarin's arm decreased to 2.44, the placebo arm was 1.58, and the average difference after the correction was 0.87 (95% CI, 0.30 to 1.44; In Pribarin's arm, 38 patients (59.4%) achieved at least 30% pain relief, compared with 21 (32.8%) in the placebo arm (P -006)The 19 patients in the former Gabalin group (29.7%) and 5 patients in the placebo group (7.8%) achieved 50% or more pain relief (P - .003)Patients who received the pre-Gabalin in the 16th week had a significantly lower total overall score in the physical and psychological areas of the former Gabalin - a brief table of pain, pain severity and functional disturbance, and WHO quality of life-BREFThere was no significant difference in the incidence of at least one adverse event experienced by the Primain arm (n s 35; 54.7%) and the placebo arm (n s 29; 45.3%) experienced at least one adverse event (P s .29), the results showed that patients with radiation-related neuropathic pain treated with Primbarin had higher pain relief, better emotional status, better quality of life, and good tolerance compared to those in the placebo group